Ovarian cancer that recurs more than 6 months following primary chemotherapy can respond to many different drugs, but retreatment with a combination of carboplatin and paclitaxel has become a standard of care. A combination of pegylated liposomal doxorubicin and carboplatin may provide a slightly, but significantly, greater therapeutic index than carboplatin and paclitaxel.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parmer, M. K. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO/OVAR-2.2 trial. Lancet 361, 2099–2106 (2003).
Pfisterer, J. et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 4699–4707 (2006).
Pujade–Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323–3329 (2010).
Markman, M. et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol. Oncol. 116, 323–325 (2010).
Syrigou, E., Makrilia, N., Koti, I., Saif, M. W. & Syrigos, K. N. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs 20, 1–6 (2009).
Vecchi, A., Mantovani, A., Tagliabue, A. & Spreafico, F. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection. Cancer Res. 36, 1222–1227 (1976).
Ehrke, M. J., Tomazic, V., Ryoyama, K., Cohen, S. A. & Mihich, E. Adriamycin induced immunomodulation: dependence upon time of administration. Int. J. Immunopharmacol. 5, 43–48 (1983).
Monk, B. J. et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28, 3107–3114 (2010).
Cannistra, S. A. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J. Clin. Oncol. 28, 3101–3103 (2010).
Bast, R. C. et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol. Oncol. 107, 173–176 (2007).
Acknowledgements
Support has been provided from the National Cancer Institute through the University of Texas MD Anderson SPORE (Specialized Program of Research Excellence) in Ovarian Cancer 1P50 CA83639.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Markman has served as a consultant for Ortho-biotech and Genentech and as a speaker for Eli Lilly. R. C. Bast Jr declares no competing interests.
Rights and permissions
About this article
Cite this article
Bast, R., Markman, M. A new standard combination for recurrent ovarian cancer?. Nat Rev Clin Oncol 7, 559–560 (2010). https://doi.org/10.1038/nrclinonc.2010.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.152
